Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080196 | 1.00 | GLP1R (0.41) | GLP1RTSHRCYP1A2KCNH2FEN1 | |
| SCHEMBL25821054 | 0.90 | GLP1R (0.39) | GLP1RTSHRKCNH2CASP1CASP7 | |
| SCHEMBL29480797 | 0.89 | GLP1R (0.42) | GLP1RTSHRCYP1A2KCNH2HRH3 | |
| SCHEMBL29480799 | 0.89 | GLP1R (0.42) | GLP1RTSHRCYP1A2KCNH2HRH3 | |
| SCHEMBL20288189 | 0.89 | GLP1R (0.42) | GLP1RTSHRCYP1A2KCNH2HRH3 | |
| SCHEMBL20280071 | 0.89 | GLP1R (0.42) | GLP1RTSHRCYP1A2KCNH2HRH3 | |
| SCHEMBL30259555 | 0.88 | GLP1R (0.41) | GLP1RTSHRCYP1A2KCNH2HRH3 | |
| SCHEMBL24338036 | 0.87 | ALDH1A1 (0.46) | GLP1RTSHRKCNH2CASP1CASP7 | |
| SCHEMBL22391724 | 0.87 | GLP1R (0.40) | GLP1RTSHRCYP1A2KCNH2CASP1 | |
| SCHEMBL24339251 | 0.87 | ALDH1A1 (0.46) | GLP1RTSHRKCNH2CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885TSHR 235/4885CYP1A2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.